Topical Dorzolamide 2%/Timolol 0.5%

Abstract

Dorzolamide/timolol is a well tolerated and effective fixed combination for lowering IOP in the treatment of open-angle glaucoma and is likely to be useful in those patients who do not respond adequately to first-line monotherapy. Compared with concomitant therapy with the same 2 drugs the primary advantage is convenience, which may lead to improved compliance. Studies of compliance and comparisons with other currently available combination therapies would be useful to fully define the value of the formulation. Nonetheless, dorzolamide combined with timolol in a single applicator system will be a useful addition to the treatment options for glaucoma, a leading cause of preventable blindness.

Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy

“…Timolol, a b-adrenergic antagonist and dorzolamide, a carbonic anhydrase inhibitor decrease IOP by inhibiting the production of aqueous humor, but through different mechanisms [25]. Previous studies have confirmed a better efficacy in lowering IOP by combination therapy than monotherapy [26][27][28] and fixed combination showed comparable clinical effect as concomitant therapy [29][30][31][32]. To our knowledge this is the first study proving the efficacy of simultaneous release of glaucoma drugs from contact lenses.…”

Evaluation of Contrast sensitivity after four different treatment modalities using optec-functional vision analyzer in primary open-angle glaucoma

“…Since their action mechanism is different, they have an additive effect when administered together. [19]…”

“…It has a purite preservative (purite is a stabilized oxychloro complex acting as an oxidative preservative that is converted into natural tear components when exposed to light) that breaks down into natural tear components and may be better tolerated in people who have allergic reactions to preservatives in other eye drops. [121319]…”